cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Iveric Bio Inc
5 own
10 watching
Current Price
$38.7
$0.67
(1.76%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
5,311.56M
52-Week High
52-Week High
38.85
52-Week Low
52-Week Low
8.85
Average Volume
Average Volume
6.8M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization5,311.56M
icon52-Week High38.85
icon52-Week Low8.85
iconAverage Volume6.8M
iconDividend Yield--
iconP/E Ratio--
What does the Iveric Bio Inc do?
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Read More
How much money does Iveric Bio Inc make?
News & Events about Iveric Bio Inc.
PR Newswire
1month ago
SHAREHOLDER ALERT: Weiss Law Investigates IVERIC bio, Inc. SHAREHOLDER ALERT: Weiss Law Investigates IVERIC bio, Inc. PR Newswire NEW YORK, May 1, 2023 NEW YORK, May 1, 2023 /PRNewswire/ -- Weiss Lawis investigating possible breaches of fiduciary duty and other violations of law by the board of...
Business Wire
1month ago
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of IVERIC bio, Inc. (NasdaqGS: ISEE) to Astellas Pharma Inc. Under the terms of the proposed transaction, shareholders of IVERIC will receive...
Globe Newswire
1month ago
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased ...
Globe Newswire
1month ago
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Iveric bio, Inc. (NASDAQ: ISEE)s sale to ...
Business Wire
1month ago
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Iveric bio, Inc. (NASDAQ: ISEE) to Astellas Pharma Inc. for $40.00 per share in cash is fair to Iveric shareholders. Halper Sadeh encourages Iveric shareholders to click here to learn more about their legal rights...
Frequently Asked Questions
Frequently Asked Questions
What is Iveric Bio Inc share price today?
plus_minus_icon
Can Indians buy Iveric Bio Inc shares?
plus_minus_icon
How can I buy Iveric Bio Inc shares from India?
plus_minus_icon
Can Fractional shares of Iveric Bio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Iveric Bio Inc stocks?
plus_minus_icon
What is today’s traded volume of Iveric Bio Inc?
plus_minus_icon
What is today’s market capitalisation of Iveric Bio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Iveric Bio Inc?
plus_minus_icon
What percentage is Iveric Bio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Iveric Bio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$38.7
$0.67
(1.76%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00